Regent Pacific Group Ltd
00575
Company Profile
Business description
Regent Pacific Group Ltd is an investment holding company that runs through two segments: Biopharma and Corporate Investment. Its Biopharma segment is engaged in the research, development, manufacturing, marketing, and sales of pharmaceutical products, and it also develops artificial intelligence (AI) systems for the field of biological aging clocks. The Corporate Investment segment is engaged in the investment in listed and unlisted corporate entities. The majority of its revenue comes from the Biopharma segment. Its geographical segments are China, Europe, Hong Kong, and Taiwan.
Contact
5 Queen's Road Central
8th Floor, Henley Building
Hong Kong
HKGT: +852 25146111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
18
Stocks News & Analysis
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.
stocks
Berkshire Hathaway earnings: Cash hits record $373 billion on mostly solid results across the firm
We think Berkshire Hathaway stock is fairly valued.
stocks
Magellan Financial Group: A dilutive acquisition of Barrenjoey
Our view of the proposed merger.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,297.20 | 103.50 | -1.10% |
| CAC 40 | 8,145.65 | 248.67 | -2.96% |
| DAX 40 | 23,693.07 | 944.93 | -3.84% |
| Dow JONES (US) | 48,838.69 | 139.23 | -0.28% |
| FTSE 100 | 10,483.57 | 296.54 | -2.75% |
| HKSE | 25,768.08 | 291.77 | -1.12% |
| NASDAQ | 22,748.86 | 80.64 | 0.36% |
| Nikkei 225 | 56,279.05 | 1,778.19 | -3.06% |
| NZX 50 Index | 13,620.21 | 102.76 | -0.75% |
| S&P 500 | 6,875.63 | 3.25 | -0.05% |
| S&P/ASX 200 | 9,077.30 | 90.80 | -0.99% |
| SSE Composite Index | 4,122.68 | 59.92 | -1.43% |